9 Déc, 2019
Tilray® s´engage dans un partenariat de recherche et d’innovation avec l’Université de Coimbra pour étudier le cannabis médical.
Strategic research partnership to support further development of cannabis-derived medical products
NANAIMO, B.C - Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis production, research, cultivation and distribution, today announced that its wholly-owned subsidiary Tilray Portugal Unipessoal Lda. (“Tilray Portugal”) has partnered with University of Coimbra to develop a first-of-its-kind strategic partnership to research and create new knowledge on cannabis-derived medical products.
Combining Tilray’s extensive expertise in cannabis cultivation, manufacturing, product development and cannabinoid science this strategic partnership will be applied to various areas within the University of Coimbra including post-graduate opportunities in chemistry, genetics and pharmaceutical sciences. The partnership will promote research project collaboration between Tilray and academic leaders at the University, leveraging Tilray’s state-of-the-art EU campus in Cantanhede and the research facilities at the Biocant research park.
Tilray’s Chief Science Officer, Dr. Joshua Eades, attended a ceremony on December 6 to celebrate the strategic partnership on campus at the University of Coimbra. The ceremony also saw the launch of the University’s work to support innovation and specialised service provision to public and private entities UC Business. The work focusses on partnerships aimed at product development, processes or services to be provided to markets in which they operate.
‘We’re proud to partner with the University of Coimbra and collaborate with their extensive team of experts and researchers to study medical cannabis,” says Dr. Eades, “The proximity to our state-of-the-art EU campus will allow our teams to collaborate on ground-breaking research contributing to the growing body of cannabinoid science, while advancing Tilray’s comprehensive research and development program.’
Tilray is committed to advancing cannabinoid science and improving the lives of patients across the world who could potentially benefit from medical cannabis. Our extensive involvement in clinical research and role in improving global patient access is critical on our mission to becoming the world’s most trusted cannabis and hemp company. By collaborating with world-leading researchers and institutions globally, medical cannabis gains credibility within the mainstream medical community and opens up potential lifesaving treatment options for patients.
The research partnership between Tilray and University of Coimbra officially began today and will continue until 2024.